Pharsight

1. List of Nucynta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593	COLLEGIUM PHARM INC	1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects	Aug, 2022 (5 months ago)
US7994364	COLLEGIUM PHARM INC	Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride	Jun, 2025 (2 years from now)

Market Authorisation Date: 20 November, 2008

Treatment: Management of moderate to severe acute pain

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg, 75 mg, and 100 mg	20 Nov, 2012	4		27 Jun, 2025
20 mg/mL	20 Dec, 2013	1		27 Jun, 2025

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 75MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

2. List of Nucynta Er drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593	COLLEGIUM PHARM INC	1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects	Aug, 2022 (5 months ago)
US7994364	COLLEGIUM PHARM INC	Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride	Jun, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11007156	COLLEGIUM PHARM INC	Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol	Oct, 2022 (3 months ago)
US8420056	COLLEGIUM PHARM INC	Abuse-proofed dosage form	Nov, 2023 (9 months from now)
US8075872	COLLEGIUM PHARM INC	Abuse-proofed dosage form	Nov, 2023 (9 months from now)
US8309060	COLLEGIUM PHARM INC	Abuse-proofed dosage form	Nov, 2023 (9 months from now)
US8114383	COLLEGIUM PHARM INC	Abuse-proofed dosage form	Oct, 2024 (1 year, 8 months from now)
US11344512	COLLEGIUM PHARM INC	Titration of tapentadol	Apr, 2028 (5 years from now)
US8536130	COLLEGIUM PHARM INC	Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain	Sep, 2028 (5 years from now)

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain; Management of neuropathic pain associated with diabetic peripheral neuropathy; A method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate; A method of titrating an opioid to manage neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg, 100 mg, 150 mg, 200 mg, and 250 mg	20 Nov, 2012	2		27 Jun, 2025

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 250MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription